Literature DB >> 2225948

Quality of well-being before and after antibiotic treatment of pulmonary exacerbation in patients with cystic fibrosis.

D M Orenstein1, E N Pattishall, P A Nixon, E A Ross, R M Kaplan.   

Abstract

General quality of life has only recently been measured with an objective tool in patients with cystic fibrosis (CF), and there have been no reported attempts to document changes in patients' overall well-being over time, as patients deteriorate or respond to intervention. We applied the Quality of Well-Being scale (QWB) in 28 patients with CF before and after a two-week course of oral ciprofloxacin used to treat pulmonary exacerbations. There were significant correlations between changes in QWB and various pulmonary function test results; QWB vs FEV1: r = 0.4, p less than 0.03; QWB vs FVC: r = 0.5, p less than 0.01; and QWB vs SaO2: r = 0.4, p less than 0.05. Thus, the QWB can track changes in general well-being in CF patients over a brief time and detect changes associated with pulmonary exacerbation and its treatment.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2225948     DOI: 10.1378/chest.98.5.1081

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  23 in total

1.  The adaptations of a quality of life questionnaire for routine use in clinical practice: the Chronic Respiratory Disease Questionnaire in cystic fibrosis.

Authors:  J Bradley; M Dempster; E Wallace; S Elborn
Journal:  Qual Life Res       Date:  1999       Impact factor: 4.147

Review 2.  Oral ciprofloxacin: a pharmacoeconomic evaluation of its use in the treatment of serious infections.

Authors:  J A Balfour; D Faulds
Journal:  Pharmacoeconomics       Date:  1993-05       Impact factor: 4.981

3.  Quality of well-being outcomes in the National Emphysema Treatment Trial.

Authors:  Robert M Kaplan; Qiankun Sun; Andrew L Ries
Journal:  Chest       Date:  2015-02       Impact factor: 9.410

4.  The revised German Cystic Fibrosis Questionnaire: validation of a disease-specific health-related quality of life instrument.

Authors:  Kerstin Wenninger; Pierre Aussage; Ulrich Wahn; Doris Staab
Journal:  Qual Life Res       Date:  2003-02       Impact factor: 4.147

5.  Development of the Cystic Fibrosis Questionnaire (CFQ) for assessing quality of life in pediatric and adult patients.

Authors:  Bernadette Henry; Pierre Aussage; Cécile Grosskopf; Jean-Marie Goehrs
Journal:  Qual Life Res       Date:  2003-02       Impact factor: 4.147

Review 6.  Quality of life in cystic fibrosis.

Authors:  D E Tullis; G H Guyatt
Journal:  Pharmacoeconomics       Date:  1995-07       Impact factor: 4.981

7.  Design and powering of cystic fibrosis clinical trials using pulmonary exacerbation as an efficacy endpoint.

Authors:  D R Vandevanter; A Yegin; W J Morgan; S J Millar; D J Pasta; M W Konstan
Journal:  J Cyst Fibros       Date:  2011-07-30       Impact factor: 5.482

Review 8.  Health-related quality of life in emphysema.

Authors:  Robert M Kaplan; Andrew L Ries
Journal:  Proc Am Thorac Soc       Date:  2008-05-01

9.  Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis.

Authors:  Jeffrey S Wagener; Lawrence Rasouliyan; Donald R VanDevanter; David J Pasta; Warren E Regelmann; Wayne J Morgan; Michael W Konstan
Journal:  Pediatr Pulmonol       Date:  2012-08-08

10.  Glycemia and the quality of well-being in patients with diabetes.

Authors:  B P Tabaei; J Shill-Novak; M Brandle; R Burke; R M Kaplan; W H Herman
Journal:  Qual Life Res       Date:  2004-08       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.